Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of calcitriol in the treatment of patients with renal osteodystrophy

Haitao Jiang¹, Xiaoming Tang¹, Cheng Zhang¹, Jian Dai¹, Haiyuan Lu²

¹Department of Orthopedics, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, No. 6, Beijing West Road, Huaiyin District, Huai'an 223300, Jiangsu Province, China; ²Department of Nephrology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, No. 6, Beijing West Road, Huaiyin District, Huai'an 223300, Jiangsu Province, China.

For correspondence:- Haiyuan Lu Email: luhaiyuan0418@163.com

Accepted: 2 February 2024 Published: 29 February 2024

Citation: Jiang H, Tang X, Zhang C, Dai J, Lu H. Efficacy of calcitriol in the treatment of patients with renal osteodystrophy. Trop J Pharm Res 2024; 23(2):355-361 doi: 10.4314/tjpr.v23i2.15

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy and prognosis of calcitriol in patients with renal osteodystrophy (ROD).

Methods: 60 patients with ROD admitted to The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, China between June 2020 and June 2021 were randomly grouped into control (n = 30) and study groups (n = 30). Patients in control group received routine management study group was treated with routine management plus calcitriol. The treatment duration was six months. Serological markers (parathyroid hormone (PTH), calcium (Ca), and phosphorus (Pi)), renal function indices (blood creatinine (SCr), urea nitrogen (BUN), and alkaline phosphatase (ALP)), as well as patients’ skeletal conditions of the spine, pelvis, and extremities were investigated. Additionally, postoperative complications and clinical efficacy were also evaluated.

Results: Study group showed significant improvement in serological markers compared to control group (p < 0.05). Also, study group had significantly reduced SCr, BUN, and ALP levels (p < 0.05) compared to control group. There was significantly reduced incidence of complications and better skeletal conditions in study group compared to control group (p < 0.05).

Conclusion: Calcitriol effectively mitigates blood-bone mechanism dysfunction and reduces the occurrence of complications in patients with ROD. However, factors such as Scr, Hb, and blood pressure affect the clinical efficacy of calcitriol on renal bone disease by mechanisms that will be investigated in the future.

Keywords: Calcitriol, Renal osteodystrophy, Clinical efficacy, Prognostic factors